Figure and Table | Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors

Table 1. Clinical Characteristic between ARPI, DTX, and Ra-223 as Second-line Treatment.

Variables	ARPI (n = 41)	DTX (n = 37)	Ra-223 (n = 10)	P-value
Median age, yrs [IQR]	76 [72-83]	74 [66-78]	73 [70-75]	0.015*
Median PSA at diagnosis, ng/ml [IQR]	40.6 [19.3-201.3]	86.5 [22.8-375.0]	56.9 [13.5-166.4]	0.68
Gleason score, n [%]
≤8	19 [47.5]	12 [33.3]	2 [20.0]	0.20
>8	21 [52.5]	24 [66.7]	8 [80.0]
Previous radical local treatment, n [%]
Absence	26 [63.4]	23 [62.2]	7 [70.0]	0.90
Presence	15 [36.6]	14 [37.8]	3 [30.0]
Median time to CRPC, mo [IQR]	19.8 [8.8, 45.7]	16.1 [9.5-27.8]	18.2 [12.0-25.4]	0.76
Lymph node metastasis at first-line treatment, n [%]
Absence	30 [73.2]	25 [67.6]	7 [70.0]	0.86
Presence	11 [26.8]	12 [32.4]	3 [30.0]
Bone metastasis at first-line treatment, n [%]
Absence	13 [31.7]	11 [29.7]	2 [20.0]	0.77
Presence	28 [68.3]	26 [70.3]	8 [80.0]
Visceral metastasis at first-line treatment, n [%]
Absence	40 [97.6]	34 [91.9]	10 [100.0]	0.37
Presence	1 [2.4]	3 [8.1]	0 [0.0]
First-line treatment agent, n [%]
Abiraterone	17 [41.5]	12 [32.4]	3 [30.0]	0.64
Enzalutamide	24 [58.5]	25 [67.6]	7 [70.0]
Median PSA at first-line treatment, ng/ml [IQR]	16.0 [7.0-49.7]	14.2 [5.1-36.5]	4.2 [3.0-9.7]	0.046*
Median time to treatment failure in first-line treatment, mo [IQR]	7.2 [3.6-14.7]	8.0 [3.1-24.5]	17.3 [8.4-23.7]	0.32
Median of maximum PSA decrease in first-line treatment, % [IQR]	−73.5 [−93.4- -41.3]	−43.8 [−82.2, 39.7]	−85.9 [−89.0, −57.3]	0.030*
Median PSA at second-line treatment, ng/ml [IQR]	24.9 [6.1-77.4]	39.0 [11.7-200.7]	8.9 [1.9-28.7]	0.10

Table 2. Univariate and Multivariate Analysis on Variables Associated with PFS.

	Univariate			Multivariate
Variables	HR	95% CI	P-value	HR	95% CI	P-value
Age
<75 years (ref)
≧75 years	1.23	0.78-1.95	0.37	1.19	0.72-1.98	0.50
Gleason score
≤8 (ref)
>8	1.31	0.82-2.08	0.26	1.32	0.77-2.25	0.31
Bone metastasis
Absence (ref)
Presence	1.35	0.79-2.31	0.28	1.01	0.56-1.81	0.99
Visceral metastasis
Absence (ref)
Presence	0.63	0.20-2.01	0.43	0.56	0.16-1.99	0.37
Time to CRPC
≧12 months (ref)
<12 months	0.89	0.55-1.43	0.62	0.66	0.38-1.14	0.14
First-line treatment agent
Abiraterone (ref)
Enzalutamide	0.96	0.59-1.54	0.85	1.29	0.75-2.21	0.36
Maximum PSA decrease during first-line treatment
≤50 % (ref)
>50 %	0.75	0.47-1.20	0.23	0.63	0.36-1.11	0.11
PSA at second-line treatment
<30 ng/ml (ref)
≧30 ng/ml	1.21	0.76-1.91	0.42	1.43	0.83-2.45	0.19
Second-line treatment
ARPI (ref)
DTX	0.60	0.37-0.99	0.046*	0.44	0.25-0.79	0.0061*
Ra-223	1.55	0.76-3.19	0.23	1.39	0.60-3.21	0.44